Global DLL3 Targeted Therapy Market Research Report 2024 - Innovations, Opportunities, Market Trends & Clinical Trials Insights
01 févr. 2024 03h16 HE
|
Research and Markets
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
18 déc. 2023 06h00 HE
|
First Wave BioPharma, Inc.
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent...
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
06 déc. 2023 08h00 HE
|
Phathom Pharmaceuticals
New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERDJuly...
Global BCR ABL Tyrosine Kinase Inhibitor Drug Market to 2029: Players Include Terns Pharmaceuticals, Theseus Pharmaceuticals, Vectura and Xspray Pharma
06 juil. 2023 05h03 HE
|
Research and Markets
Dublin, July 06, 2023 (GLOBE NEWSWIRE) -- The "Global BCR ABL Tyrosine Kinase Inhibitor Drug Market, Drug Price, Sales & Clinical Trials Insight 2029" report has been added to ...
Global Biosimilars Business and Investment Opportunities 2023: Sector to Reach $42.3 Billion by 2026 at a 22% CAGR
18 avr. 2023 05h58 HE
|
Research and Markets
Dublin, April 18, 2023 (GLOBE NEWSWIRE) -- The "Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals,...
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
11 avr. 2023 05h00 HE
|
Paradigm Biopharmaceuticals
MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Australia’s Paradigm Biopharmaceuticals Ltd (ASX:PAR) says analysis of six-month trial data shows injectable pentosan polysulfate sodium...
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
08 janv. 2023 18h00 HE
|
Phathom Pharmaceuticals
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data...
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
24 oct. 2022 08h00 HE
|
Phathom Pharmaceuticals
A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S.Topline data for the primary endpoint is expected in Q1 2023 with full trial...
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
30 sept. 2022 06h15 HE
|
Zealand Pharma
Company announcement – No. 41 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1) Glepaglutide treatment met the...
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
19 sept. 2022 02h00 HE
|
Zealand Pharma
Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...